

# Author Index

Absi L, 214  
 Ackerley CA, 271  
 Ager J, 618  
 Agid Y, 257  
 Albanese A, 362  
 Alexander CJ, 35  
 Alkadhri H, 384  
 Almer G, 176  
 Alperovitch A, 411  
 Amer G, 263  
 Amyes ER, 253  
 Anand I, 117  
 Andermann F, 770  
 Andersen P, 643  
 Andrade DM, 271  
 Antel SB, 770  
 Antoine J-C, 214  
 Antonini A, 155  
 Antozzi C, 106  
 Arai H, 276  
 Arai H, 544  
 Archelos JJ, 135  
 Archer SA, 320  
 Arimura K, 544  
 Armelle Cheval M, 607  
 Arnold DL, 770  
 Arnold SE, 165  
 Asmus F, 121  
 Averbach B, 7

Bagli M, 819  
 Baiger M, 130  
 Ball WS, 401  
 Ballaban-Gil K, 328  
 Baloh RW, 800  
 Banin E, 278  
 Baram TZ, 304  
 Barker PB, 423  
 Barkow K, 819  
 Barnes LF, 761  
 Barthélemy C, 607  
 Basu S, 114  
 Baulac M, 786  
 Baulac S, 786  
 Baumgärtner U, 493  
 Beal MF, 561  
 Beaudry P, 257  
 Becker G, 405  
 Benaim E, 222  
 Benarroch EE, 146  
 Benecke R, 536  
 Bennett D, 202  
 Bentivoglio AR, 362  
 Berg AT, 659

Berg D, 121  
 Berg D, 405  
 Berghold A, 135  
 Berkovic SF, 45  
 Bernasconi A, 770  
 Bernasconi N, 770  
 Berry-Kravis E, 98  
 Bertram L, 114  
 Bertram M, 121  
 Bezman L, 186  
 Bezman L, 512  
 Bhidayasiri R, 24  
 Bird ED, 29  
 Bird T, 486  
 Bird TD, 144  
 Bird TD, 817  
 Birnbaum G, 135  
 Bitsch A, 793  
 Black JT, 396  
 Blacker D, 114  
 Blamire AM, 590  
 Blandini F, 525  
 Bock N, 393  
 Boecker H, 813  
 Bokil HS, 24  
 Booth G, 98  
 Bottos C, 257  
 Bowman LC, 222  
 Bowser R, 249  
 Bradley JL, 590  
 Brandel J-P, 257  
 Breiter JCS, 418  
 Bresolin N, 137  
 Brice A, 117  
 Brice A, 786  
 Briellmann RS, 45  
 Briolotti V, 267  
 Broderick J, 736  
 Broe GA, 125  
 Brooks WS, 125  
 Brott T, 736  
 Brown GK, 805  
 Brown H, 808  
 Brown RH, 130  
 Brown RM, 805  
 Bruce J, 165  
 Brück W, 793  
 Brunson KL, 304  
 Buerger K, 545  
 Buldyrev I, 808  
 Burstein AH, 706  
 Bushara KO, 540  
 Bushby KMD, 443  
 Bynevelt M, 477  
 Byrnes ML, 320  
 Calamante F, 477  
 Calne DB, 298  
 Camdessanché J-P, 214  
 Camu W, 267  
 Camuzat A, 117

Capone A, 518  
 Cappai R, 125  
 Carnero C, 263  
 Carrara F, 106  
 Cassetta E, 362  
 Castelon Konkiewitz E, 813  
 Cavanagh J, 313  
 Ceballos-Baumann A, 121  
 Ceballos-Baumann AO, 813  
 Cecil KM, 401  
 Chan D, 433  
 Chan E, 271  
 Chapin J, 776  
 Chatterjee S, 345  
 Chelimsky TC, 453  
 Chémali KR, 453  
 Chen C, 176  
 Chew N-K, 810  
 Chiba H, 544  
 Chinnery PF, 443  
 Cho HS, 697  
 Chong H-T, 810  
 Chong WK, 805  
 Chow T, 355  
 Chu Y, 202  
 Chua, K-B, 810  
 Chuck G, 401  
 Chugani DC, 618  
 Chugani HT, 618  
 Cipolotti L, 433  
 Clark CM, 165  
 Classen J, 536  
 Clatterbuck RE, 682  
 Clavelou P, 267  
 Clayton D, 665  
 Cochran EJ, 202  
 Cohen J, 328  
 Collins DL, 770  
 Comi G, 290  
 Comi G, 415  
 Comi GP, 137  
 Conant K, 230  
 Conforto A, 345  
 Connelly A, 477  
 Conrad B, 813  
 Conway JE, 682  
 Cooper JM, 590  
 Corbett D, 230  
 Corona P, 106  
 Costa AF, 529  
 Cotton RGH, 125  
 Cox TC, 477  
 Crilley JG, 590  
 Crino PB, 67  
 Croen LA, 597  
 Cross AH, 396  
 Crum WR, 433  
 Crystal A, 114  
 Cullen M, 443  
 Cummings JL, 280  
 Cummings JL, 355  
 Cunningham JM, 222

Cupples LA, 29  
 Cutting LE, 279  
 Dalakas MC, 532  
 Dalmau JO, 141  
 Damasio A, 53  
 Dambrosia JM, 597  
 Daniel S, 665  
 Daniels G, 384  
 Darin N, 377  
 Davies M, 470  
 Davies P, 545  
 Davis MB, 362  
 De Jonghe P, 245  
 De La Fuente-Fernandez R, 298  
 De Pasqua V, 668  
 De Silva R, 665  
 DeGrauw TJ, 401  
 DeKosky ST, 202  
 Del Bigio MR, 727  
 Del Bo R, 137  
 Del Favero J, 245  
 DeLong MR, 142  
 Deng A, 114  
 Devinsky O, 575  
 Dhawan V, 155  
 Diaz J, 607  
 Dichgans M, 121  
 Dickens BF, 597  
 Dicker E, 328  
 D'Incerti L, 106  
 Dittmann R, 585  
 Dixon P, 665  
 Dixon PH, 362  
 Dowling P, 776  
 Dubeau F, 770  
 Ducimetière P, 411  
 Dufouil C, 411  
 Dugan LL, 627  
 Durner M, 328  
 Dürr A, 117  
 Dütsch M, 575  
 Ebersberger A, 7  
 Eghbal-Ahmadi M, 304  
 Eidelberg D, 155  
 Elpeleg O, 195  
 Escolar DM, 706  
 Esiri MM, 253  
 Espinosa G, 408  
 Evans JPM, 477  
 Evgrafov O, 245  
 Fagan SC, 736  
 Fardeau M, 607  
 Fawcett PRW, 443  
 Feingold J, 786  
 Feinstein DL, 276  
 Fernandez M, 486  
 Ferrar MD, 753

# Author Index

Absi L, 214  
 Ackerley CA, 271  
 Ager J, 618  
 Agid Y, 257  
 Albanese A, 362  
 Alexander CJ, 35  
 Alkadhri H, 384  
 Almer G, 176  
 Alperovitch A, 411  
 Amer G, 263  
 Amyes ER, 253  
 Anand I, 117  
 Andermann F, 770  
 Andersen P, 643  
 Andrade DM, 271  
 Antel SB, 770  
 Antoine J-C, 214  
 Antonini A, 155  
 Antozzi C, 106  
 Arai H, 276  
 Arai H, 544  
 Archelos JJ, 135  
 Archer SA, 320  
 Arimura K, 544  
 Armelle Cheval M, 607  
 Arnold DL, 770  
 Arnold SE, 165  
 Asmus F, 121  
 Averbach B, 7

Bagli M, 819  
 Baiger M, 130  
 Ball WS, 401  
 Ballaban-Gil K, 328  
 Baloh RW, 800  
 Banin E, 278  
 Baram TZ, 304  
 Barker PB, 423  
 Barkow K, 819  
 Barnes LF, 761  
 Barthélemy C, 607  
 Basu S, 114  
 Baulac M, 786  
 Baulac S, 786  
 Baumgärtner U, 493  
 Beal MF, 561  
 Beaudry P, 257  
 Becker G, 405  
 Benaim E, 222  
 Benarroch EE, 146  
 Benecke R, 536  
 Bennett D, 202  
 Bentivoglio AR, 362  
 Berg AT, 659

Berg D, 121  
 Berg D, 405  
 Berghold A, 135  
 Berkovic SF, 45  
 Bernasconi A, 770  
 Bernasconi N, 770  
 Berry-Kravis E, 98  
 Bertram L, 114  
 Bertram M, 121  
 Bezman L, 186  
 Bezman L, 512  
 Bhidayasiri R, 24  
 Bird ED, 29  
 Bird T, 486  
 Bird TD, 144  
 Bird TD, 817  
 Birnbaum G, 135  
 Bitsch A, 793  
 Black JT, 396  
 Blacker D, 114  
 Blamire AM, 590  
 Blandini F, 525  
 Bock N, 393  
 Boecker H, 813  
 Bokil HS, 24  
 Booth G, 98  
 Bottos C, 257  
 Bowman LC, 222  
 Bowser R, 249  
 Bradley JL, 590  
 Brandel J-P, 257  
 Breiter JCS, 418  
 Bresolin N, 137  
 Brice A, 117  
 Brice A, 786  
 Briellmann RS, 45  
 Briolotti V, 267  
 Broderick J, 736  
 Broe GA, 125  
 Brooks WS, 125  
 Brott T, 736  
 Brown GK, 805  
 Brown H, 808  
 Brown RH, 130  
 Brown RM, 805  
 Bruce J, 165  
 Brück W, 793  
 Brunson KL, 304  
 Buerger K, 545  
 Buldyrev I, 808  
 Burstein AH, 706  
 Bushara KO, 540  
 Bushby KMD, 443  
 Bynevelt M, 477  
 Byrnes ML, 320  
 Calamante F, 477  
 Calne DB, 298  
 Camdessanché J-P, 214  
 Camu W, 267  
 Camuzat A, 117

Capone A, 518  
 Cappai R, 125  
 Carnero C, 263  
 Carrara F, 106  
 Cassetta E, 362  
 Castelon Konkiewitz E, 813  
 Cavanagh J, 313  
 Ceballos-Baumann A, 121  
 Ceballos-Baumann AO, 813  
 Cecil KM, 401  
 Chan D, 433  
 Chan E, 271  
 Chapin J, 776  
 Chatterjee S, 345  
 Chelimsky TC, 453  
 Chémali KR, 453  
 Chen C, 176  
 Chew N-K, 810  
 Chiba H, 544  
 Chinnery PF, 443  
 Cho HS, 697  
 Chong H-T, 810  
 Chong WK, 805  
 Chow T, 355  
 Chu Y, 202  
 Chua, K-B, 810  
 Chuck G, 401  
 Chugani DC, 618  
 Chugani HT, 618  
 Cipolotti L, 433  
 Clark CM, 165  
 Classen J, 536  
 Clatterbuck RE, 682  
 Clavelou P, 267  
 Clayton D, 665  
 Cochran EJ, 202  
 Cohen J, 328  
 Collins DL, 770  
 Comi G, 290  
 Comi G, 415  
 Comi GP, 137  
 Conant K, 230  
 Conforto A, 345  
 Connelly A, 477  
 Conrad B, 813  
 Conway JE, 682  
 Cooper JM, 590  
 Corbett D, 230  
 Corona P, 106  
 Costa AF, 529  
 Cotton RGH, 125  
 Cox TC, 477  
 Crilley JG, 590  
 Crino PB, 67  
 Croen LA, 597  
 Cross AH, 396  
 Crum WR, 433  
 Crystal A, 114  
 Cullen M, 443  
 Cummings JL, 280  
 Cummings JL, 355  
 Cunningham JM, 222

Cupples LA, 29  
 Cutting LE, 279  
 Dalakas MC, 532  
 Dalmau JO, 141  
 Damasio A, 53  
 Dambrosia JM, 597  
 Daniel S, 665  
 Daniels G, 384  
 Darin N, 377  
 Davies M, 470  
 Davies P, 545  
 Davis MB, 362  
 De Jonghe P, 245  
 De La Fuente-Fernandez R, 298  
 De Pasqua V, 668  
 De Silva R, 665  
 DeGrauw TJ, 401  
 DeKosky ST, 202  
 Del Bigio MR, 727  
 Del Bo R, 137  
 Del Favero J, 245  
 DeLong MR, 142  
 Deng A, 114  
 Devinsky O, 575  
 Dhawan V, 155  
 Diaz J, 607  
 Dichgans M, 121  
 Dickens BF, 597  
 Dicker E, 328  
 D'Incerti L, 106  
 Dittmann R, 585  
 Dixon P, 665  
 Dixon PH, 362  
 Dowling P, 776  
 Dubeau F, 770  
 Ducimetière P, 411  
 Dufouil C, 411  
 Dugan LL, 627  
 Durner M, 328  
 Dürr A, 117  
 Dütsch M, 575  
 Ebersberger A, 7  
 Eghbal-Ahmadi M, 304  
 Eidelberg D, 155  
 Elpeleg O, 195  
 Escolar DM, 706  
 Esiri MM, 253  
 Espinosa G, 408  
 Evans JPM, 477  
 Evgrafov O, 245  
 Fagan SC, 736  
 Fardeau M, 607  
 Fawcett PRW, 443  
 Feingold J, 786  
 Feinstein DL, 276  
 Fernandez M, 486  
 Ferrar MD, 753

- Ferraris A, 362  
 Ferriero DM, 820  
 Fiebach JB, 460  
 Filippi M, 290  
 Filippi M, 415  
 Fischbeck KH, 706  
 Fitzek C, 493  
 Fitzek S, 493  
 Fitzsimons RB, 753  
 Flowers JM, 643  
 Font J, 408  
 Ford B, 761  
 Forss N, 90  
 Foster NL, 416  
 Fotheringham J, 727  
 Fox NC, 433  
 Frachon P, 607  
 Francis MJ, 405  
 Frants RR, 753  
 Frey KA, 285  
 Frey KA, 416  
 Friend JC, 29  
 Frontali M, 362  
 Frucht S, 761  
 Fuchs S, 121  
 Fujigasaki H, 117  
 Fujino H, 685  
 Fukuda M, 155  
 Fulthorpe JJ, 443  
 Fursdon Davis CJ, 253  
  
 Gabreëls-Festen A, 797  
 Gadian DG, 477  
 Gailloud P, 682  
 Galasko D, 165  
 Gallano P, 130  
 Gallardo E, 130  
 Gansted U, 672  
 Garakian J, 355  
 García T, 263  
 Gasser T, 121  
 Genin E, 786  
 Ghaemi M, 367  
 Ghez C, 155  
 Ghilardi MF, 155  
 Gibson GJ, 443  
 Gieffers J, 585  
 Giger JD, 727  
 Go R, 114  
 Goadsby PJ, 4  
 Goebel SU, 540  
 Goh K-J, 810  
 Goldfarb LG, 540  
 Goldmann C, 636  
 Gómez-Tortosa E, 29  
 Gonzalez G, 650  
 Goodridge DM, 336  
 Gorodeski R, 453  
 Goutieres F, 607  
 Grabowski TJ, 697  
 Graf W, 486  
 Graham E, 665  
 Greenamyre JT, 525  
 Greenberg DA, 328  
 Greenberg SM, 697  
 Grether JK, 597  
  
 Griesmann GE, 146  
 Griffin JW, 694  
 Gropman AL, 706  
 Grossman M, 165  
 Gross-Tsur V, 278  
 Grotta JC, 736  
 Guégan C, 176  
 Guénette S, 114  
 Gusella JF, 29  
  
 Haan J, 753  
 Haass A, 585  
 Hacke W, 460  
 Hadley DW, 706  
 Haley EC, 736  
 Hall SM, 470  
 Hallett M, 540  
 Halliday G, 313  
 Hallupp M, 125  
 Hamada C, 138  
 Hamed S, 706  
 Hammerstad J, 155  
 Hampel H, 545  
 Hand CK, 267  
 Hanefeld F, 585  
 Hansen RL, 597  
 Harden C, 328  
 Hart PE, 590  
 Hartung H-P, 135  
 Hasegawa M, 501  
 Hashemi-Nejad A, 521  
 Hashimoto T, 242  
 Hayashi S, 14  
 Hayashi S, 712  
 Hays AP, 176  
 Hays AP, 249  
 Heiland S, 460  
 Heinrich H, 393  
 Heiss W-D, 367  
 Helton KJ, 222  
 Heneka MT, 276  
 Hennig J, 518  
 Hergersberg M, 384  
 Herholz K, 367  
 Herman A, 786  
 Hertz S, 328  
 Hess K, 384  
 Hetta J, 136  
 Heun R, 819  
 Heywood P, 753  
 Higuchi I, 544  
 Higuchi S, 276  
 Higuchi S, 544  
 Hilker R, 367  
 Hilz MJ, 575  
 Hirai H, 544  
 Hirata K, 712  
 Hirsch E, 786  
 Hoffman EP, 706  
 Hohlfeld R, 281  
 Holden J, 650  
 Holden JE, 298  
 Holme E, 377  
 Holmes SE, 117  
 Holopainen IE, 110  
 Holtkamp M, 260  
  
 Honnorat J, 214  
 Hooper DC, 139  
 Hopf HC, 493  
 Horstink MWIM, 797  
 Horwitz EM, 222  
 Houlden H, 521  
 Hua Y, 67  
 Hudgson P, 443  
 Hughes S, 253  
 Hyman BT, 114  
 Hyman BT, 808  
  
 Ialongo T, 362  
 Ianzano L, 271  
 Ikeda S-I, 242  
 Ikeda S-I, 546  
 Illa I, 130  
 Imbimbo BP, 416  
 Iwaki H, 544  
 Iwatsubo T, 501  
 Izquierdo G, 529  
 Izumi Y, 242  
  
 Jackson C, 736  
 Jackson GD, 45  
 Jacobson KM, 800  
 Jakobs C, 401  
 Jamieson S, 443  
 Jamot L, 117  
 Janisse JJ, 618  
 Jansen O, 460  
 Jardine PE, 753  
 Jelliffe LL, 597  
 Jen JC, 800  
 Jivan S, 298  
 Johnson AL, 336  
 Johnson MA, 443  
 Johnson RT, 1  
 Johnson RT, 820  
 Johnston JB, 230  
 Johnston JB, 650  
 Jones J, 114  
 Juhász C, 618  
 Jung HH, 384  
  
 Kabus C, 121  
 Kaipur J, 820  
 Kaji R, 138  
 Kamarulzaman A, 810  
 Kamijo M, 712  
 Kang H, 328  
 Kapoor R, 470  
 Karjalainen T, 90  
 Karpati G, 693  
 Kasama T, 712  
 Kass NE, 512  
 Katai S, 242  
 Kaup FJ, 636  
 Keddache MA, 328  
 Keeney D, 114  
 Khan N, 304  
 Khan N, 665  
 Khoris J, 267  
 Ki C-S, 817  
 Kilbourn MR, 416  
 Kim DK, 817  
  
 Kim HJ, 817  
 Kim JL, 24  
 Kim J-W, 817  
 Kim K-K, 146  
 Kimura M, 276  
 King RHM, 521  
 Kirkham FJ, 477  
 Kis B, 367  
 Klein C, 367  
 Klepper J, 685  
 Klotz I, 328  
 Klotz K, 585  
 Kneifel S, 384  
 Kockler M, 819  
 Koeppe RA, 416  
 Koga M, 712  
 Kohnken R, 545  
 Kokkonen H, 110  
 Kokubo Y, 501  
 Koller W, 155  
 Kollias S, 384  
 Kölsch H, 819  
 Kopp N, 214  
 Koprowski H, 139  
 Kordower JH, 202  
 Korpi ER, 110  
 Kors EE, 753  
 Kothari R, 736  
 Koyanagi A, 685  
 Krämer M, 636  
 Krametter D, 135  
 Krance R, 222  
 Kremer BPH, 797  
 Kril JJ, 125  
 Kruse N, 405  
 Kryzer TJ, 146  
 Kuhl DE, 416  
 Kuhlmann T, 793  
 Kunesch E, 536  
 Kunjapan SR, 810  
 Kuzuhara S, 501  
 Kwok JBJ, 125  
  
 Labar DR, 328  
 Ladkani D, 415  
 Lam, S-K, 810  
 Lamantea E, 106  
 Landreth GE, 276  
 Lang A, 155  
 Laplanche JL, 257  
 Lasa A, 130  
 Lassmann H, 793  
 Lebre A-S, 117  
 Lee CS, 298  
 Lee V M-Y, 165  
 Lees A, 665  
 LeGuern E, 786  
 Leigh PN, 643  
 Leigh RJ, 24  
 Lennon VA, 146  
 Lenz O, 367  
 Leschziner G, 433  
 Levine SR, 688  
 Levine SR, 736  
 Lévy C, 411  
 Lhatoo SD, 336

- Li M, 532  
 Li W, 776  
 Lin L, 136  
 Lipe H, 486  
 Lipkin WI, 249  
 Lochmuller H, 693  
 Lodi R, 590  
 Loeffen J, 195  
 Loes DJ, 186  
 Lombès A, 607  
 Long DM, 817  
 Lotharius J, 79  
 Louis ED, 761  
 Love S, 753  
 Lozano AM, 155  
 Lu J-Q, 298  
 Lu M, 736  
 Lublin FD, 677  
 Lucas M, 529  
 Lucchinetti C, 793  
 Luciano D, 328  
 Lücke W, 636  
 Lyden PD, 736  
 Lynch DR, 67  
 Lyons K, 155
- Maass M, 585  
 MacDonald BK, 336  
 MacDonald ME, 29  
 Maeda Y, 776  
 Maertzdorf J, 104  
 Magerl W, 493  
 Magistris M, 214  
 Maier W, 819  
 Mandel H, 195  
 Mander A, 665  
 Manner TE, 110  
 Manners D, 590  
 Margolis RL, 117  
 Marler JR, 736  
 Martin E, 518  
 Martin J-J, 245  
 Maruyama M, 544  
 Maruyama T, 242  
 Marx J, 493  
 Mascia A, 668  
 Masliah E, 165  
 Mastaglia FL, 320  
 Masterman DM, 355  
 Masters CL, 125  
 Mathias CJ, 521  
 Matsuda C, 130  
 Matsui T, 544  
 Matsumoto S, 138  
 Matsuno S, 546  
 Matsushita M, 486  
 Matsushita S, 276  
 Matsushita S, 544  
 Mayeux R, 808  
 Mayeux-Portas V, 267  
 Mayne M, 727  
 McArthur JC, 745  
 McInnis M, 114  
 McLean CA, 125  
 Mega MS, 355  
 Melberg A, 136
- Menonna J, 776  
 Mentis M, 155  
 Mersivanova I, 245  
 Mesulam M-M, 425  
 Metsähonkala EL, 110  
 Metz LM, 650  
 Mezaki T, 138  
 Michel D, 214  
 Mignot E, 136  
 Müller JQ, 278  
 Minassian BA, 271  
 Minoshima S, 416  
 Mizutani K, 138  
 Moeller H-J, 545  
 Mohr A, 460  
 Moll GH, 393  
 Mondell BE, 418  
 Montalban X, 408  
 Montori M, 529  
 Moreno JD, 558  
 Morgan DJ, 396  
 Morikawa Y-I, 544  
 Morita H, 546  
 Morris C, 665  
 Moser AB, 396  
 Moser AB, 512  
 Moser HW, 186  
 Moser HW, 396  
 Moser HW, 512  
 Moshe SL, 328  
 Moshe SL, 659  
 Moslemi A-R, 377  
 Mosnier J-F, 214  
 Mufson EJ, 202  
 Mukoyama I, 138  
 Müller-Myhsok B, 121  
 Mullin K, 114  
 Murphy K, 682  
 Muzik O, 618  
 Myers RH, 29
- Na DK, 817  
 Nagarajan L, 320  
 Nägren K, 110  
 Naini A, 176  
 Nakagawa M, 544  
 Nakazato F, 242  
 Nappi G, 525  
 Narita Y, 501  
 Naumann M, 121  
 Naumann M, 405  
 Nayak S, 24  
 Nelis E, 245  
 Nelson KB, 597  
 Nelson PK, 575  
 Ni W, 230  
 Nicholson GA, 125  
 Nicholson GA, 313  
 Niederwieser G, 135  
 Nishino S, 136
- Odaka M, 712  
 Ogier De Baulny H, 607  
 Oh AK, 800  
 Ohnishi A, 712  
 Okamura N, 544
- Oldfors A, 377  
 Oliva R, 263  
 Olivier A, 770  
 O'Malley KL, 79  
 Oppenheimer S, 555  
 Orakcioglu B, 460  
 Osame M, 544  
 Osawa Y, 685  
 Osterhaus ADME, 104  
 Ottman R, 761  
 Ozelius LJ, 367
- Palmer J, 130  
 Pancioli A, 736  
 Papassotiropoulos A, 819  
 Parkkola RK, 110  
 Parvizi J, 53  
 Pastor E, 263  
 Pastor P, 263  
 Peeling J, 727  
 Peoc'h K, 257  
 Perini MP, 137  
 Perrine K, 575  
 Petersen RC, 421  
 Petiot P, 214  
 Petri Henske E, 67  
 Petry H, 636  
 Pfeiffer RF, 820  
 Phillips TM, 597  
 Picard F, 786  
 Pickhardt M, 636  
 Pike GB, 770  
 Pohl D, 585  
 Pohlers O, 460  
 Portlance Walker M, 249  
 Posner JB, 141  
 Powell JF, 643  
 Power C, 230  
 Power C, 650  
 Power C, 727  
 Powers JM, 396  
 Praamstra P, 797  
 Pramstaller PP, 367  
 Prud'Homme J-F, 786  
 Pruszk-Seel R, 121  
 Przedborski S, 176  
 Ptok U, 819
- Quick KL, 627  
 Quinn N, 665  
 Quinn TC, 556  
 Quistorff B, 672
- Rahman S, 805  
 Rajagopalan B, 590  
 Ramat S, 24  
 Rao ML, 819  
 Rapoport SI, 545  
 Raskind W, 486  
 Ratan RR, 345  
 Rauhut U, 575  
 Rausch W-D, 405  
 Raymond GV, 186  
 Raymond GV, 512  
 Rebeck GW, 114  
 Rebeck GW, 697
- Reilly M, 521  
 Reinert K, 405  
 Reingold SC, 677  
 Resor SR, 328  
 Reverter JC, 408  
 Richter F, 7  
 Rieckmann P, 405  
 Rigamonti D, 682  
 Ringleb PA, 460  
 Ripley B, 136  
 Rojas-García R, 130  
 Romero N, 607  
 Rosen R, 35  
 Rosenbaum D, 328  
 Rosenblatt DS, 396  
 Rosoklija G, 176  
 Ross CA, 117  
 Ross CA, 14  
 Rossini PM, 136  
 Rossor AM, 433  
 Rossor MN, 433  
 Rothenberger A, 393  
 Rothman SM, 721  
 Rouleau GA, 267  
 Rovaris M, 415  
 Ruth TJ, 298  
 Ryssel H, 460  
 Ryu H, 345
- Sakamoto T, 138  
 Sakurai S, 546  
 Salomons GS, 401  
 Sander JWAS, 336  
 Sándor PS, 668  
 Sartor K, 460  
 Sasaki H, 544  
 Sasaki R, 501  
 Sastre-Garriga J, 408  
 Saxena R, 117  
 Scahill RI, 433  
 Scarlato G, 137  
 Schaible H-G, 7  
 Schapira AHV, 590  
 Schaumburg H, 817  
 Scheithauer B, 67  
 Schellenberg GD, 144  
 Schellinger PD, 460  
 Scherer SW, 271  
 Schiess R, 384  
 Schlaberg R, 249  
 Schmidt RE, 396  
 Schmitz S, 819  
 Schneider J, 518  
 Schoenen J, 668  
 Schofield PR, 125  
 Schulzer M, 298  
 Schwab S, 460  
 Schwaiger M, 813  
 Seerp Baarsma G, 104  
 Seidel L, 668  
 Sengers R, 195  
 Serrano-Munuera C, 130  
 Shahar EL, 278  
 Shalev R, 278  
 Shalinsky DR, 230  
 Sharpe DM, 313

- Shaw CE, 643  
 Sheikh KA, 694  
 Shibasaki H, 138  
 Shill H, 540  
 Shimada H, 546  
 Shimohata T, 14  
 Shinnar R, 659  
 Shinnar S, 328  
 Shinnar S, 659  
 Shorvon SD, 336  
 Shuck T, 165  
 Silén T, 90  
 Silva C, 230  
 Silva C, 650  
 Sinke RJ, 797  
 Sipski ML, 35  
 Smeets R, 195  
 Smeitink J, 195  
 Smith C, 808  
 Smith KD, 512  
 Smith KJ, 470  
 Smith MJ, 125  
 Snead OC, 288  
 Solanky M, 776  
 Solano F, 529  
 Solbach W, 585  
 Somers JT, 24  
 Sormani MP, 415  
 Sossi V, 298  
 Spira PJ, 313  
 Spitsin SV, 139  
 Srinidhi J, 29  
 Stadelmann C, 793  
 Stebbins GT, 202  
 Steen RG, 222  
 Stefan K, 536  
 Steiner T, 460  
 Stephan C, 585  
 Stevens JM, 433  
 Stöckler-Ipsiroglu S, 195  
 Stoessl AJ, 298  
 Stoeter P, 493  
 Strasser-Fuchs S, 135  
 Strazzer S, 137  
 Strotmann T, 367  
 Styles P, 590  
 Suehara M, 544  
 Susuki K, 712
- Sutton IJ, 253
- Tada T, 242  
 Taga T, 685  
 Tagawa Y, 712  
 Takahashi H, 14  
 Takahashi H, 712  
 Takamatsu N, 138  
 Takano T, 685  
 Takeda A, 276  
 Tamaoka A, 546  
 Tamargo RJ, 682  
 Tan C-T, 810  
 Tanaka K, 686  
 Tanaka M, 686  
 Tang M-X, 808  
 Tanzi R, 114  
 Tarnopolsky MA, 561  
 Taylor A, 98  
 Taylor DJ, 590  
 Taylor SAM, 29  
 Teipel SJ, 545  
 Teismann P, 176  
 Tekin S, 355  
 Tennekoon G, 688  
 Terry RD, 684  
 Terwindt GM, 753  
 Thayaparan T, 810  
 Thickbroom GW, 320  
 Thiel T, 518  
 Thomas PK, 521  
 Thömke F, 493  
 Thompson KA, 745  
 Thompson S, 222  
 Tilley BC, 736  
 Timmerman V, 245  
 Tintoré M, 408  
 Tiranti V, 106  
 Tojo M, 544  
 Tokuda T, 546  
 Tolosa E, 263  
 Tomasini L, 328  
 Tong X, 260  
 Torn-Broers Y, 45  
 Touboul P-J, 411  
 Treede R-D, 493  
 Treib J, 585  
 Trijbels F, 195
- Trojanowski JQ, 165  
 Trott G-E, 393  
 Tsuji S, 14  
 Tulinius M, 377  
 Tzourio C, 411
- Ueda S, 712  
 Urban P, 493
- Valente EM, 362  
 Valentino LA, 98  
 Van Alfen N, 797  
 Van Broeckhoven C, 245  
 Van Deerlin VMD, 165  
 Van Den Heuvel L, 195  
 Van Den Maagdenberg  
 AMJM, 753  
 Van Der Lelij A, 104  
 Van Eimeren T, 813  
 Van Geel BM, 186  
 Van Hoesen GW, 53  
 Vanhatalo S, 277  
 Vaughan J, 665  
 Vela R, 263  
 Verbeek MM, 685  
 Verhoeven NM, 401  
 Verjans GMGM, 104  
 Verma IC, 117  
 Vermeulen FMLG, 753  
 Verrips A, 685  
 Vieregge P, 367  
 Vincent A, 253  
 Vinters HV, 355  
 Vinters HV, 691  
 Vissing J, 672  
 Vogelsberg-Ragaglia V, 165  
 Voit T, 685  
 Vonsattel J-P, 29  
 Vonsattel JPG, 697
- Wagner KR, 706  
 Walker MC, 260  
 Wallace S, 328  
 Walls TJ, 443  
 Wang WC, 222  
 Warren KG, 650  
 Watkins PR, 512  
 Weber F, 636
- Weber T, 636  
 Wee Yong V, 230  
 Weigell-Weber M, 384  
 Weiler LJ, 29  
 Weishaupt A, 405  
 Welaratne A, 257  
 Wesselingh SL, 745  
 Whelan C, 808  
 White R, 67  
 Whitwell JL, 433  
 Wiendl H, 281  
 Willemsen MAAP, 685  
 Wilson CJ, 805  
 Wirth S, 393  
 Wolff J, 486  
 Wolinsky JS, 290  
 Wolinsky JS, 415  
 Wong B, 401  
 Wood JD, 14  
 Wood N, 665  
 Wood NW, 362  
 Wood NW, 521
- X-Tang M, 761
- Yabana T, 501  
 Yamada M, 14  
 Yamada M, 712  
 Yamada Y, 242  
 Yan H-J, 727  
 Yang X-F, 721  
 Yhu S, 114  
 Yohai D, 328  
 Young EJ, 271  
 Young P, 636  
 Yu Z, 146  
 Yuen E, 486  
 Yuki N, 712
- Zaman K, 345  
 Zander C, 117,  
 Zayas MD, 529  
 Zeviani M, 106  
 Zhang K, 230  
 Zhukareva V, 165  
 Zimprich A, 121  
 Zinkowski R, 545  
 Zwarts, MJ 797



# Subject Index

## **N-Acetylaspartate**

absence of N-acetylaspartate in the human brain: impact on neurospectroscopy? (Martin et al) 2001;49:518

N-acetyl aspartate-a neuronal marker? (Barker) 2001;49:423 (Editorial)

## **Acetylcholinesterase**

central acetylcholinesterase inhibition in Alzheimer patients (Imbimbo) 2001;49:416 (Letter)

## **ACTH**

corticotropin (ACTH) acts directly on amygdala neurons to down-regulate corticotropin-releasing hormone gene expression (Brunson et al) 2001;49:304

how does ACTH work against infantile spasms? Bedside to bench (Snead) 2001;49:288 (Editorial)

## **Adenosine**

adenosine A<sub>2A</sub> receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage (Mayne et al) 2001;49:EEE

diminished adenosine A<sub>1</sub> receptor expression on macrophages in brain and blood of patients with multiple sclerosis (Johnston et al) 2001;49:650

## **Adrenocorticotrophic hormone; see ACTH**

## **Adrenoleukodystrophy**

adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening (Bezman et al) 2001;49:512

evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy (Van Geel et al) 2001;49:186

## **Aging; see also Elderly**

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

## **AIDS; see HIV-1**

## **Alpers' syndrome**

sequence-selective DNA binding drugs mithramycin A and chromomycin A<sub>3</sub> are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons (Chatterjee et al) 2001;49:345

## **Alzheimer's disease**

cathepsin D polymorphism not associated with Alzheimer's disease in Japan (Matsui et al) 2001;49:544 (Letter)

focal dementia syndromes: in search of the gold standard (Petersen) 2001;49:421 (Editorial)

honorable compromise regarding amyloid in Alzheimer's disease (Terry) 2001;49:684 (Letter)

lack of association of the interleukin-1 $\beta$  gene polymorphism with Alzheimer's disease in a Korean population (Ki et al) 2001;49:UUU (Letter)

orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease (Tekin et al) 2001;49:355

patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease (Chan et al) 2001;49:433

role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease (Heneka et al) 2001;49:276 (Letter)

tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231 (Hampel et al) 2001;49:545 (Letter)

## **Alzheimer's disease, genetics**

no evidence for genetic association or linkage of the cathepsin D (CTSD) exon 2 polymorphism and Alzheimer disease (Bertram et al) 2001;49:114

selective vulnerability of brainstem nuclei to Alzheimer's disease (Parvizi et al) 2001;49:53

## **Alzheimer's disease, pathology**

central acetylcholinesterase inhibition in Alzheimer patients (Imbimbo) 2001;49:416 (Letter)

selective vulnerability of brainstem nuclei to Alzheimer's disease (Parvizi et al) 2001;49:53

variable phenotype of Alzheimer's disease with spastic paraparesis (Smith et al) 2001;49:125

## **Amphetamine**

role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity (Lotharius and O'Malley) 2001;49:79

## **Amyloid**

cerebral amyloid angiopathy: a microvascular link between parenchymal and vascular dementia? 2001;49:GGG (Editorial)

honorable compromise regarding amyloid in Alzheimer's disease (Terry) 2001;49:684 (Letter)

novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy (Grabowski et al) 2001;49:HHH

plasma levels of amyloid  $\beta$  proteins did not differ between subjects taking statins and those not taking statins (Tokuda et al) 2001;49:546 (Letter)

## **Amyotrophic lateral sclerosis**

absence of echovirus sequences in brain and spinal cord of amyotrophic lateral sclerosis patients (Walker et al) 2001;49:249

compound heterozygous D90A and D96N SOD1 mutations in a recessive amyotrophic lateral sclerosis family (Hand et al) 2001;49:267

effects of riluzole on cortical excitability in patients with amyotrophic lateral sclerosis (Stefan et al) 2001;49:536

familial amyotrophic lateral sclerosis and parkinsonism-dementia complex of the Kii Peninsula of Japan: clinical and neuropathological study and tau analysis (Kuzuhara et al) 2001;49:501

increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis (Almer et al) 2001;49:176

intron 7 retention and exon 9 skipping EAAT2 mRNA variants are not associated with amyotrophic lateral sclerosis (Flowers et al) 2001;49:643

## **Aneurysm**

treatment of intracranial aneurysm: surgical clipping or endovascular coiling? (Tamargo et al) 2001;49:682 (Letter)

## **Angelman syndrome**

decreased binding of [<sup>11</sup>C]flumazenil in Angelman syndrome patients with GABAA receptor  $\beta$ 3 subunit deletions (Holopainen et al) 2001;49:110

## Angioma

germline mutations in the *CCM1* gene, encoding Krit1, cause cerebral cavernous malformations (Lucas et al) 2001;49:529

## Annals of Neurology

message from the editor (Johnson) 2001;49:1 (Editorial)

## Antibodies

anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis (Sastre-Garriga et al) 2001;49:408

anti-Yo antibodies and cerebellar degeneration in a man with adenocarcinoma of the esophagus (Sutton et al) 2001;49:253

CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity (Yu et al) 2001;49:146

paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy (Antoine et al) 2001;49:214

yet another paraneoplastic antibody (Posner and Dalmau) 2001;49:141 (Editorial)

## Anticardiolipin antibodies

anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis (Sastre-Garriga et al) 2001;49:408

## Antioxidants

antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia (Lodi et al) 2001;49:590

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

## Aphasia

primary progressive aphasia (Mesulam) 2001;49:425

## Apolipoprotein E

apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke (Broderick et al) 2001;49:736

Parkinson's disease is not associated with the combined (alpha symbol)-synuclein/apolipoprotein E susceptibility genotype (Khan et al) 2001;49:665

## Apoptosis

adenosine A<sub>2A</sub>/A<sub>2B</sub> receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage (Mayne et al) 2001;49:EEE

correlation between neurological progression and astrocyte apoptosis in HIV-associated dementia (Thompson et al) 2001;49:745

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

sequence-selective DNA binding drugs mithramycin A and chromomycin A<sub>3</sub> are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons (Chatterjee et al) 2001;49:345

## Astrocytes

correlation between neurological progression and astrocyte apoptosis in HIV-associated dementia (Thompson et al) 2001;49:745

## Ataxia

antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia (Lodi et al) 2001;49:590

intermediate CAG repeat lengths (53,54) for MJD/SCA3 are associated with an abnormal phenotype (Alfen et al) 2001;49:797

slowing of voluntary and involuntary saccades: an early sign in spinocerebellar ataxia type 7 (Oh et al) 2001;49:800

## Ataxia telangiectasia

superoxide stress identifies neurons at risk in a model of ataxia-telangiectasia (Quick and Dugan) 2001;49:627

## Atrophin-1

widespread occurrence of intranuclear atrophin-1 accumulations in the CNS neurons of patients with dentatorubral-pallidoluysian atrophy (Yamada et al) 2001;49:14

## Atrophy

loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment (Kordower et al) 2001;49:202

patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease (Chan et al) 2001;49:433

widespread occurrence of intranuclear atrophin-1 accumulations in the CNS neurons of patients with dentatorubral-pallidoluysian atrophy (Yamada et al) 2001;49:14

## Attention deficit-hyperactivity disorder

children with comorbid attention-deficit-hyperactivity disorder and tic disorder: evidence for additive inhibitory deficits within the motor system (Moll et al) 2001;49:393

## Aura

migraine, aura, and cortical spreading depression: why are we still talking about it? (Goadsby) 2001;49:4 (Editorial)

## Autism

neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation (Nelson et al) 2001;49:597

## Autoantibodies

CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity (Yu et al) 2001;49:146

## Autonomic nervous system

hemispheric influence on autonomic modulation and baroreflex sensitivity (Hilz et al) 2001;49:575

## Autonomic neuropathy

a novel TRK A (*NTRK1*) mutation associated with hereditary sensory and autonomic neuropathy type V (Houlden) 2001;49:521

## Axons

electrically active axons degenerate when exposed to nitric oxide (Smith et al) 2001;49:470

## Baroreflexes

hemispheric influence on autonomic modulation and baroreflex sensitivity (Hilz et al) 2001;49:575

## Basal ganglia

subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease (Blandini et al) 2001;49:525

## Books

*Aids to the Examination of the Peripheral Nervous System*, 4th ed by O'Brien (Johnson) 2001;49:820

*Alzheimer Disease: The Changing View* by Katzman and Bick (Breitner) 2001;49:418

- Alzheimer's Disease: The Changing View* by Katzman and Bick 2001;49:418
- Atlas of Digital Polysomnography* by Geyer et al (Allen) 2001;49:548
- Brain Mapping: The Disorders* edited by Mazziotta et al (Hillis) 2001;49:551
- Brain Mapping: The Systems* edited by Toga and Mazziotta (Hillis) 2001;49:551
- Central Nervous System Angiitis* by Schmidley (Levine) 2001;49:688
- Cluster Headache and Related Conditions*, edited by Olesen and Goadsby (Mondell) 2001;49:418
- Cluster Headache and Related Conditions* edited by Olesen and Goadsby (Mondell) 2001;49:418
- Comprehensive Clinical Neurophysiology* by Luders and Levin (Conwit) 2001;49:549
- Developmental Disability & Behavior* edited by Gillberg and O'Brien (Kinsman) 2001;49:549
- GABA in the Nervous System: The View at 50 Years* edited by Olsen (Kapur) 2001;49:820
- Infectious Diseases of the Nervous System* edited by Davis and Kennedy (Johnson) 2001;49:552
- Molecular Mechanisms of Neurodegenerative Diseases* edited by Chesselet (Koo) 2001;49:551
- Neurobiology of Spinal Cord Injury* by Kalb and Strittmatter (Tennekoon) 2001;49:688
- Neuroimaging* edited by Orrison (Masdeu) 2001;49:550
- Neurology of Eye Movements, 3rd ed* by Leigh and Zee (Sharpe) 2001;49:548
- Neurology of the Newborn, 4th ed.* by Volpe (Ferriero) 2001;49:820
- New Concepts in the Immunopathogenesis of CNS Infections* edited by Peterson and Remington (Johnson) 2001;49:552
- Parkinson's Disease and Movement Disorders* edited by Adler & Ahlskog (Pfeiffer) 2001;49:821
- The Practice of Neural Science from Synapses to Symptoms* by Brust (Miller) 2001;49:279
- Principles of Behavioral and Cognitive Neurology, 2nd ed.* edited by Mesulam (Cummings) 2001;49:280
- Reading and Attention Disorders* edited by Duane (Cutting) 2001;49:279
- Brainstem**  
selective vulnerability of brainstem nuclei to Alzheimer's disease (Parvizi et al) 2001;49:53
- Cancer**  
anti-Yo antibodies and cerebellar degeneration in a man with adenocarcinoma of the esophagus (Sutton et al) 2001;49:253  
CRMP-5 neuronal autoantibody: marker for lung cancer and thymoma-related autoimmunity (Yu et al) 2001;49:146  
paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy (Antoine et al) 2001;49:214  
yet another paraneoplastic antibody (Posner and Dalmau) 2001;49:141 (Editorial)
- Cardiomyopathy**  
antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedrich's ataxia (Lodi et al) 2001;49:590  
mutations in the complex I *NDUFS2* gene of patients with cardiomyopathy and encephalomyopathy (Loeffen et al) 2001;49:195

## Cardiovascular system

- forebrain lateralization of cardiovascular function: physiology and clinical correlates (Oppenheimer) 2001;49:555 (Editorial)  
hemispheric influence on autonomic modulation and baroreflex sensitivity (Hilz et al) 2001;49:575

## Carnitine

- potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

## Cathepsin D

- cathepsin D polymorphism not associated with Alzheimer's disease in Japan (Matsui et al) 2001;49:544 (Letter)  
no evidence for genetic association or linkage of the cathepsin D (*CTSD*) exon 2 polymorphism and Alzheimer disease (Bertram et al) 2001;49:114

## Cerebellar ataxia

- gluten sensitivity in sporadic and hereditary cerebellar ataxia (Bushara et al) 2001;49:540

## Cerebellar disease

- anti-Yo antibodies and cerebellar degeneration in a man with adenocarcinoma of the esophagus (Sutton et al) 2001;49:253  
are transfectant cells essential for measuring cytotoxic T cells in paraneoplastic cerebellar degeneration? (Tanaka and Tanaka) 2001;49:686 (Letter)  
SCA12 is a rare locus for autosomal dominant cerebellar ataxia: a study of an Indian family (Fujigasaki et al) 2001;49:117  
subclinical cerebellar impairment in the common types of migraine: a three-dimensional analysis of reaching movements (Sándor et al) 2001;49:668

## Cerebral amyloid angiopathy

- cerebral amyloid angiopathy: a microvascular link between parenchymal and vascular dementia? (Vinters) 2001;49:691 (Editorial)  
novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy (Grabowski et al) 2001;49:697

## Cerebral blood flow

- low cerebral blood flow velocity and risk of white matter hyperintensities (Tzourio et al) 2001;49:411

## Cerebral cavernous angioma

- germline mutations in the *CCM1* gene, encoding Krit1, cause cerebral cavernous malformations (Lucas et al) 2001;49:529

## Cerebral cortex

- differences in sensory and motor cortical organization following brain injury early in life (Thickbroom et al) 2001;49:320  
migraine, aura, and cortical spreading depression: why are we still talking about it? (Goadsby) 2001;49:4 (Editorial)  
right lateralized motor cortex activation during volitional blinking (Eimeren et al) 2001;49:813  
selective alterations in glutamate and GABA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers (White et al) 2001;49:67  
sequence-selective DNA binding drugs mithramycin A and chromomycin A<sub>3</sub> are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons (Chatterjee et al) 2001;49:345

## Cerebral edema

- delayed cerebral edema and fatal coma after minor head trauma: role of CACNA1A calcium channel subunit



gene and relationship with familial hemiplegic migraine (Kors et al) 2001;49:753

#### **Cerebral hemorrhage**

adenosine A<sub>2A</sub> receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage (Mayne et al) 2001;49:727

#### **Cerebral infarction**

mechanisms and predictors of chronic facial pain in lateral medullary infarction (Fitzek et al) 2001;49:493

#### **Cerebral ischemia**

improved cerebrovascular patency following therapy in patients with sickle cell disease: initial results in 4 patients who received HLA-identical hematopoietic stem cell allografts (Steen et al) 2001;49:222

stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia (Schellinger et al) 2001;49:460

#### **Cerebral lateralization**

hemispheric influence on autonomic modulation and baroreflex sensitivity (Hilz et al) 2001;49:575

#### **Cerebral palsy**

differences in sensory and motor cortical organization following brain injury early in life (Thickbroom et al) 2001;49:320

#### **Cerebrospinal fluid**

14-3-3 protein cerebrospinal fluid detection in human growth hormone-treated Creutzfeldt-Jakob disease (Brandel et al) 2001;49:257

cerebrospinal fluid interleukin-6 levels in hypertensive encephalopathy: a possible marker of disease activity (Takano et al) 2001;49:685 (Letter)

hypoglycorrhachia: a simple clue, simply missed (Willemssen et al) 2001;49:685 (Letter)

presence of *Chlamydia pneumoniae* DNA in the cerebral spinal fluid is a common phenomenon in a variety of neurological diseases and not restricted to multiple sclerosis (Gieffers et al) 2001;49:585

tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231 (Hampel et al) 2001;49:545 (Letter)

#### **Cerebrovascular disorders**

apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke (Broderick et al) 2001;49:736

improved cerebrovascular patency following therapy in patients with sickle cell disease: initial results in 4 patients who received HLA-identical hematopoietic stem cell allografts (Steen et al) 2001;49:222

stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia (Schellinger et al) 2001;49:460

tracking post-stroke recovery with magnetoencephalography (Rossini) 2001;49:136 (Letter)

#### **Ceruloplasmin**

decreased serum ceruloplasmin and copper levels in cervical dystonia (Mezaki et al) 2001;49:138 (Letter)

#### **Cervical dystonia**

decreased serum ceruloplasmin and copper levels in cervical dystonia (Mezaki et al) 2001;49:138 (Letter)

#### **Charcot-Marie-Tooth disease**

further evidence that neurofilament light chain gene mutations can cause Charcot-Marie-Tooth disease type 2E (De Jonghe et al) 2001;49:245

#### **Children**

care should be taken in interpretation of visual field tests in children (Vanhatalo) 2001;49:277 (Letter)

children with comorbid attention-deficit-hyperactivity disorder and tic disorder: evidence for additive inhibitory deficits within the motor system (Moll et al) 2001;49:393

how long do new-onset seizures in children last? (Shinnar et al) 2001;49:659

neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation (Nelson et al) 2001;49:597

postnatal maturation of human GABA<sub>A</sub> receptors measured with positron emission tomography (Chugani et al) 2001;49:618

#### ***Chlamydia pneumoniae***

*Chlamydia pneumoniae* and multiple sclerosis: innocent bystander or culprit? (Quinn) 2001;49:557 (Editorial)

*Chlamydia pneumoniae*-specific humoral immune responses and clinical disease parameters in multiple sclerosis (Krametter et al) 2001;49:135 (Letter)

presence of *Chlamydia pneumoniae* DNA in the cerebral spinal fluid is a common phenomenon in a variety of neurological diseases and not restricted to multiple sclerosis (Gieffers et al) 2001;49:585

#### **Chromomycin A3**

sequence-selective DNA binding drugs mithramycin A and chromomycin A<sub>3</sub> are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons (Chatterjee et al) 2001;49:345

#### **Clinical trials**

placebo-controlled clinical trials in multiple sclerosis: ethical considerations (Lublin et al) 2001;49:677

placebos on trial (Moreno) 2001;49:558 (Editorial)

#### **Cobalamin**

neurological and neuropathological heterogeneity in two brothers with cobalamin C deficiency (Powers et al) 2001;49:396

#### **Coenzyme Q10**

antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia (Lodi et al) 2001;49:590

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

#### **Coma**

delayed cerebral edema and fatal coma after minor head trauma: role of CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine (Kors et al) 2001;49:753

#### **Convulsions; see Seizures**

#### **Copper**

decreased serum ceruloplasmin and copper levels in cervical dystonia (Mezaki et al) 2001;49:138 (Letter)

reduction of Menkes mRNA and copper in leukocytes of patients with primary adult-onset dystonia (Kruse et al) 2001;49:405

#### **Cortical dysplasia**

texture analysis of morphological processing of magnetic resonance imaging assist detection of focal cortical dysplasia in extra-temporal partial epilepsy (Bernasconi et al) 2001;49:770

#### **Cortical spreading depression**

is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? (Ebersberger et al) 2001;49:7  
migraine, aura, and cortical spreading depression: why are we still talking about it? (Goadsby) 2001;49:4

**Corticotropin; see ACTH****Creatine**

irreversible brain creatine deficiency with elevated serum and urine creatine: a creatine transporter defect? (Cecil et al) 2001;49:401

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

**Creutzfeldt-Jakob disease**

14-3-3 protein cerebrospinal fluid detection in human growth hormone-treated Creutzfeldt-Jakob disease (Brandel et al) 2001;49:257

**Cyclooxygenase-2**

increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis (Almer et al) 2001;49:176

**Deep brain stimulation**

deep brain stimulation for Parkinson's disease (Delong and Wichmann) 2001;49:142 (Editorial)

functional correlates of pallidal stimulation for Parkinson's disease (Fukuda et al) 2001;49:155

**Dementia**

the case of the missing tau, or, why didn't the mRNA bark? (Bird and Schellenberg) 2001;49:144 (Editorial)

cerebral amyloid angiopathy: a microvascular link between parenchymal and vascular dementia? (Vinters) 2001;49:691 (Editorial)

correlation between neurological progression and astrocyte apoptosis in HIV-associated dementia (Thompson et al) 2001;49:745

familial amyotrophic lateral sclerosis and parkinsonism-dementia complex of the Kii Peninsula of Japan: clinical and neuropathological study and tau analysis (Kuzuhara et al) 2001;49:501

familial atypical progressive supranuclear palsy associated with homozygosity for the delN296 mutation in the tau gene (Pastor et al) 2001;49:263

focal dementia syndromes: in search of the gold standard (Petersen) 2001;49:421 (Editorial)

HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors (Johnston et al) 2001;49:230

loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment (Kordower et al) 2001;49:202

loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia (Zhukareva et al) 2001;49:165

novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy (Grabowski et al) 2001;49:697

patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease (Chan et al) 2001;49:433

**Dentatorubral-pallidolysian atrophy**

widespread occurrence of intranuclear atrophin-1 accumulations in the CNS neurons of patients with dentatorubral-pallidolysian atrophy (Yamada et al) 2001;49:14

**Depression**

is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? (Ebersberger et al) 2001;49:7

migraine, aura, and cortical spreading depression: why are we still talking about it? (Goadsby) 2001;49:4 (Editorial)

**Desmin**

abnormal desmin protein in myofibrillar myopathies caused by desmin gene mutations (Li and Dalakas) 2001;49:532

*Diagnostic and Statistical Manual of Mental Disorders* (DSM-IV)\_122-123,123t

**Dichloroacetate**

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

**DNA**

sequence-selective DNA binding drugs mithramycin A and chromomycin A<sub>3</sub> are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons (Chatterjee et al) 2001;49:345

**DNA, mitochondrial**

Down's syndrome fibroblasts anticipate the accumulation of specific ageing-related mtDNA mutations (Del Bo et al) 2001;137:138

incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA abnormalities (Darin et al) 2001;49:377

late-onset mitochondrial DNA depletion: DNA copy number, multiple deletions, and compensation (Barthélémy et al) 2001;49:607

novel mtDNA mutation in the ND5 subunit of complex I in two MELAS patients (Corona et al) 2001;49:106

**Dopamine**

biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover (Fuente-Fernández et al) 2001;49:298

no evidence of association between a dopamine transporter gene polymorphism (1215A/G) and Parkinson's disease (Kimura et al) 2001;49:276 (Letter)

positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the *Parkin* gene (Hilker et al) 2001;49:367

role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity (Lotharius and O'Malley) 2001;49:79

**Down regulation**

corticotropin (ACTH) acts directly on amygdala neurons to down-regulate corticotropin-releasing hormone gene expression (Brunson et al) 2001;49:304

**Down's syndrome**

Down's syndrome fibroblasts anticipate the accumulation of specific ageing-related mtDNA mutations (Del Bo et al) 2001;137:138

**Drug therapy**

placebos on trial (Moreno) 2001;49:558 (Editorial)

**Dyskinesia**

familial dyskinesia and facial myokymia (FDFM): a novel movement disorder (Fernandez et al) 2001;49:486

**Dystonia**

abnormal activity in the globus pallidus in off-period dystonia (Hashimoto et al) 2001;49:242

decreased serum ceruloplasmin and copper levels in cervical dystonia (Mezaki et al) 2001;49:138 (Letter)

DYT13, a novel primary torsion dystonia locus, maps to chromosome 1p36.13-36.32 in an Italian family with cranial-cervical or upper limb onset (Valente et al) 2001;49:362

- reduction of Menkes mRNA and copper in leukocytes of patients with primary adult-onset dystonia (Kruse et al) 2001;49:405
- Echoviruses**  
absence of echovirus sequences in brain and spinal cord of amyotrophic lateral sclerosis patients (Walker et al) 2001;49:249
- Elderly**  
loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment (Kordower et al) 2001;49:202
- Encephalitis**  
HSV-1-induced retinitis following herpes simplex encephalitis: indications for brain-to-eye transmission of HSV-1 (Maertzdorf et al) 2001;49:104  
treatment of acute Nipah encephalitis with ribavirin (Chong et al) 2001;49:810
- Encephalomyopathy**  
incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA abnormalities (Darin et al) 2001;49:377
- Encephalopathy**  
cerebrospinal fluid interleukin-6 levels in hypertensive encephalopathy: a possible marker of disease activity (Takano et al) 2001;49:685 (Letter)  
mutations in the complex I *NDUFS2* gene of patients with cardiomyopathy and encephalomyopathy (Loeffen et al) 2001;49:195
- Epilepsy**  
bruising and the ketogenic diet: evidence for diet-induced changes in platelet function (Berry-Kravis et al) 2001;49:98  
causes of epilepsies: insights from discordant monozygotic twins (Briellmann et al) 2001;49:45  
evidence for digenic inheritance in a family with both febrile convulsions and temporal lobe epilepsy implicating chromosomes 18qter and 1q25-q31 (Baulac et al) 2001;49:786  
genome scan of idiopathic generalized epilepsy: evidence for major susceptibility gene and modifying genes influencing the seizure type (Durner et al) 2001;49:328  
lack of activation of human secondary somatosensory cortex in Unverricht-Lundborg type of progressive myoclonus epilepsy (Forss et al) 2001;49:90  
laforin is a cell membrane and endoplasmic reticulum-associated protein tyrosine phosphatase (Minassian et al) 2001;49:271  
mortality in epilepsy in the first 11 to 14 years after diagnosis: multivariate analysis of a long-term, prospective, population-based cohort (Lhatoo et al) 2001;49:336  
propofol in subanesthetic doses terminates status epilepticus in a rodent model (Holtkamp et al) 2001;49:260  
selective alterations in glutamate and GABA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers (White et al) 2001;49:67  
texture analysis of morphological processing of magnetic resonance imaging assist detection of focal cortical dysplasia in extra-temporal partial epilepsy (Bernasconi et al) 2001;49:770
- Erratum**  
factors predicting prognosis of epilepsy after presentation with seizures (MacDonald et al) 2001;49:547
- Essential tremor**  
risk of tremor and impairment from tremor in relatives of patients with essential tremor: a community-based family study (Louis et al) 2001;49:761
- Eye movements**  
ocular oscillations induced by shifts of the direction and depth of visual fixation (Bhidayasiri et al) 2001;49:24
- Familial dyskinesia and facial myokymia**  
familial dyskinesia and facial myokymia (FDFM): a novel movement disorder (Fernandez et al) 2001;49:486
- Flumazenil**  
decreased binding of [<sup>3</sup>H]flumazenil in Angelman syndrome patients with GABAA receptor  $\beta$ 3 subunit deletions (Holopainen et al) 2001;49:110
- Focal cortical dysplasia**  
texture analysis of morphological processing of magnetic resonance imaging assist detection of focal cortical dysplasia in extra-temporal partial epilepsy (Bernasconi et al) 2001;49:770
- Forebrain**  
forebrain lateralization of cardiovascular function: physiology and clinical correlates (Oppenheimer) 2001;49:555 (Editorial)
- Friedreich's ataxia**  
antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia (Lodi et al) 2001;49:590
- Frontotemporal dementia**  
the case of the missing tau, or, why didn't the mRNA bark? (Bird and Schellenberg) 2001;49:144 (Editorial)  
loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia (Zhukareva et al) 2001;49:165
- GABA**  
postnatal maturation of human GABA<sub>A</sub> receptors measured with positron emission tomography (Chugani et al) 2001;49:618
- GABA receptor**  
decreased binding of [<sup>3</sup>H]flumazenil in Angelman syndrome patients with GABA<sub>A</sub> receptor  $\beta$ 3 subunit deletions (Holopainen et al) 2001;49:110  
selective alterations in glutamate and GABA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers (White et al) 2001;49:67
- Gangliosides**  
animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside (Yuki et al) 2001;49:712  
Genetic mutations; see Mutations
- Gentamicin**  
gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations (Wagner et al) 2001;49:706  
when running a stop sign may be a good thing (Karpati) 2001;49:693 (Editorial)
- Ginkgo biloba**  
potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561
- Glatiramer acetate**  
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on MRI-measured disease activity and

- burden in patients with relapsing multiple sclerosis (Comi et al) 2001;49:290
- Global Assessment of Functioning (GAF) Scale\_123,124t**
- Globus pallidus**  
abnormal activity in the globus pallidus in off-period dys-tonia (Hashimoto et al) 2001;49:242
- Glucose**  
hypoglycorrhachia: a simple clue, simply missed (Willem-sen et al) 2001;49:685 (Letter)
- Glutamate**  
intron 7 retention and exon 9 skipping EAAT2 mRNA variants are not associated with amyotrophic lateral sclerosis (Flowers et al) 2001;49:643  
selective alterations in glutamate and GABA receptor sub-unit mRNA expression in dysplastic neurons and giant cells of cortical tubers (White et al) 2001;49:67
- GM1 ganglioside**  
animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside (Yuki et al) 2001;49:712
- Guillain-Barré syndrome**  
animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside (Yuki et al) 2001;49:712
- Headache**  
delayed cerebral edema and fatal coma after minor head trauma: role of CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine (Kors et al) 2001;49:753  
is there a correlation between spreading depression, neu-rogenic inflammation, and nociception that might cause migraine headache? (Ebersberger et al) 2001;49:7  
migraine, aura, and cortical spreading depression: why are we still talking about it? (Goadsby) 2001;49:4  
subclinical cerebellar impairment in the common types of migraine: a three-dimensional analysis of reaching movements (Sándor et al) 2001;49:668
- Head trauma**  
delayed cerebral edema and fatal coma after minor head trauma: role of CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine (Kors et al) 2001;49:753
- Heart**  
antioxidant treatment improves in vivo cardiac and skele-tal muscle bioenergetics in patients with Friedreich's ataxia (Lodi et al) 2001;49:590
- Hemispheric lateralization**  
hemispheric influence on autonomic modulation and baroreflex sensitivity (Hilz et al) 2001;49:575  
right lateralized motor cortex activation during volitional blinking (Eimeren et al) 2001;49:813
- Herpes simplex virus**  
HSV-1-induced retinitis following herpes simplex enceph-alitis: indications for brain-to-eye transmission of HSV-1 (Maertzdorf et al) 2001;49:104
- Human immunodeficiency virus**  
correlation between neurological progression and astrocyte apoptosis in HIV-associated dementia (Thompson et al) 2001;49:745  
HIV-1 Tat neurotoxicity is prevented by matrix metallo-proteinase inhibitors (Johnston et al) 2001;49:230
- Huntington's disease**  
quantitative neuropathological changes in presymptomatic Huntington's disease (Gómez-Tortosa et al) 2001;49:29
- Hypertensive encephalopathy**  
cerebrospinal fluid interleukin-6 levels in hypertensive en-cephalopathy: a possible marker of disease activity (Ta-kano et al) 2001;49:685 (Letter)
- Hypocretin**  
hypocretin deficiency in familial symptomatic narcolepsy (Melberg et al) 2001;49:136 (Letter)
- Hypoglycorrhachia**  
hypoglycorrhachia: a simple clue, simply missed (Willem-sen et al) 2001;49:685 (Letter)
- Interleukin-1**  
gene polymorphisms of interleukin-1(alpha symbol) influ-ence the course of Alzheimer's disease (Kölsch et al) 2001;49:818 (Letter)  
lack of association of the interleukin-1(alpha symbol) gene polymorphism with Alzheimer's disease in a Korean population (Ki et al) 2001;49:817 (Letter)
- Interleukin-6**  
cerebrospinal fluid interleukin-6 levels in hypertensive en-cephalopathy: a possible marker of disease activity (Ta-kano et al) 2001;49:685 (Letter)
- Japan**  
cathepsin D polymorphism not associated with Alzhei-mer's disease in Japan (Matsui et al) 2001;49:544 (Let-ter)  
familial amyotrophic lateral sclerosis and parkinsonism-dementia complex of the Kii Peninsula of Japan: clini-cal and neuropathological study and tau analysis (Ku-zuhara et al) 2001;49:501
- Kearns Sayre syndrome**  
late-onset mitochondrial DNA depletion: DNA copy number, multiple deletions, and compensation (Bar-thélémy et al) 2001;49:607
- Ketogenic diet**  
bruising and the ketogenic diet: evidence for diet-induced changes in platelet function (Berry-Kravis et al) 2001;49:98
- Korea**  
lack of association of the interleukin-1(alpha symbol) gene polymorphism with Alzheimer's disease in a Korean population (Ki et al) 2001;49:817 (Letter)
- Lactic acidosis**  
exercise intolerance in mitochondrial myopathy is not re-lated to lactic acidosis (Vissing et al) 2001;49:672
- Lafora disease**  
laforin is a cell membrane and endoplasmic reticulum-associated protein tyrosine phosphatase (Minassian et al) 2001;49:271
- Leigh's syndrome**  
sequence-selective DNA binding drugs mithramycin A and chromomycin A/d3/d are potent inhibitors of neu-ronal apoptosis induced by oxidative stress and DNA damage in cortical neurons (Chatterjee et al) 2001;49:345
- Leukodystrophy**  
SURF1 gene mutation presenting as isolated leukodystro-phy (Rahman et al) 2001;49:805
- Levodopa**  
the neurochemistry of therapeutics: levodopa pharmacody-namics in Parkinson's disease (Frey) 2001;49:285 (Ed-itorial)



**Lipoic acid**

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

**Lung cancer**

CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity (Yu et al) 2001;49:146

**Machado-Joseph disease**

intermediate CAG repeat lengths (53,54) for MJD/SCA3 are associated with an abnormal phenotype (Alfen et al) 2001;49:797

**Magnetic resonance imaging**

absence of *N*-acetylaspartate in the human brain: impact on neurospectroscopy? (Martin et al) 2001;49:518

*N*-acetyl aspartate-a neuronal marker? (Barker) 2001;49:423 (Editorial)

effects of seasons on magnetic resonance imaging-measured disease activity in patients with multiple sclerosis (Rovaris et al) 2001;49:415 (Letter)

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on MRI-measured disease activity and burden in patients with relapsing multiple sclerosis (Comi et al) 2001;49:290

a longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions (Bitsch et al) 2001;49:793

perfusion magnetic resonance abnormalities in patients with sickle cell disease (Kirkham et al) 2001;49:477

stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia (Schellinger et al) 2001;49:460

texture analysis of morphological processing of magnetic resonance imaging assist detection of focal cortical dysplasia in extra-temporal partial epilepsy (Bernasconi et al) 2001;49:770

**Magnetic resonance spectroscopy**

irreversible brain creatine deficiency with elevated serum and urine creatine: a creatine transporter defect? (Cecil et al) 2001;49:401

**Magnetoencephalography**

tracking post-stroke recovery with magnetoencephalography (Rossini) 2001;49:136 (Letter)

**Matrix metalloproteinases**

HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors (Johnston et al) 2001;49:230

**McLeod syndrome**

McLeod syndrome: a novel mutation, predominant psychiatric manifestations, and distinct striatal imaging findings (Jung et al) 2001;49:384

**MELAS syndrome**

novel mtDNA mutation in the ND5 subunit of complex I in two MELAS patients (Corona et al) 2001;49:106

**Menkes protein**

reduction of Menkes mRNA and copper in leukocytes of patients with primary adult-onset dystonia (Kruse et al) 2001;49:405

**Mental retardation**

neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation (Nelson et al) 2001;49:597

**Mental status examination 122**

format for 122f

**Messenger RNA; see RNA, messenger****Migraine**

delayed cerebral edema and fatal coma after minor head trauma: role of CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine (Kors et al) 2001;49:753

is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? (Ebersberger et al) 2001;49:7

migraine, aura, and cortical spreading depression: why are we still talking about it? (Goadsby) 2001;49:4

Editorial

subclinical cerebellar impairment in the common types of migraine: a three-dimensional analysis of reaching movements (Sándor et al) 2001;49:668

**Mithramycin A**

sequence-selective DNA binding drugs mithramycin A and chromomycin A/d3/d are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons (Chatterjee et al) 2001;49:345

**Mitochondria**

exercise intolerance in mitochondrial myopathy is not related to lactic acidosis (Vissing et al) 2001;49:672

incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA abnormalities (Darin et al) 2001;49:377

role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity (Lotharius and O'Malley) 2001;49:79

Mitochondrial DNA *see* DNA, mitochondrial

**MK801**

subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease (Blandini et al) 2001;49:525

**Motor cortex**

right lateralized motor cortex activation during volitional blinking (Eimeren et al) 2001;49:813

**Motor hyperactivity**

children with comorbid attention deficit-hyperactivity disorder and tic disorder: evidence for additive inhibitory deficits within the motor system (Moll et al) 2001;49:393

**Movement disorders**

abnormal activity in the globus pallidus in off-period dystonia (Hashimoto et al) 2001;49:242

decreased serum ceruloplasmin and copper levels in cervical dystonia (Mezaki et al) 2001;49:138 (Letter)

DYT13, a novel primary torsion dystonia locus, maps to chromosome 1p36.13-36.32 in an Italian family with cranial-cervical or upper limb onset (Valente et al) 2001;49:362

familial dyskinesia and facial myokymia (FDFM): a novel movement disorder (Fernandez et al) 2001;49:486

familial dyskinesia and facial myokymia (FDFM): a novel movement disorder (Fernandez et al) 2001;49:486

reduction of Menkes mRNA and copper in leukocytes of patients with primary adult-onset dystonia (Kruse et al) 2001;49:405

risk of tremor and impairment from tremor in relatives of patients with essential tremor: a community-based family study (Louis et al) 2001;49:761

**mRNA *see* RNA, messenger****Multiple sclerosis**

*Chlamydia pneumoniae*-specific humoral immune responses and clinical disease parameters in multiple sclerosis (Krametter et al) 2001;49:135 (Letter)

placebo-



- controlled clinical trials in multiple sclerosis: ethical considerations (Lublin et al) 2001;49:677
- presence of *Chlamydia pneumoniae* DNA in the cerebral spinal fluid is a common phenomenon in a variety of neurological diseases and not restricted to multiple sclerosis (Gieffers et al) 2001;49:585
- Multiple sclerosis, diagnosis**
- anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis (Sastre-Garriga et al) 2001;49:408
- Multiple sclerosis, etiology**
- Chlamydia pneumoniae* and multiple sclerosis: innocent bystander or culprit? (Quinn) 2001;49:557 (Editorial)
- Multiple sclerosis, imaging**
- effects of seasons on magnetic resonance imaging-measured disease activity in patients with multiple sclerosis (Rovaris et al) 2001;49:415 (Letter)
- a longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions (Bitsch et al) 2001;49:793
- Multiple sclerosis, pathology**
- diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis (Johnston et al) 2001;49:650
- platelet-derived growth factor-(alpha symbol) receptor-positive oligodendroglia are frequent in multiple sclerosis lesions (Maeda et al) 2001;49:776
- Multiple sclerosis, treatment**
- European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on MRI-measured disease activity and burden in patients with relapsing multiple sclerosis (Comi et al) 2001;49:290
- placebos on trial (Moreno) 2001;49:558 (Editorial)
- prospects for the treatment of multiple sclerosis by raising serum levels of uric acid, a scavenger of peroxynitrite (Koprowski) 2001;49:139 (Letter)
- Multiple sclerosis, treatment**
- The ups and downs of multiple sclerosis therapeutics (Hohlfeld & Wiendl) 2001;49:281 (Editorial)
- Multiple sclerosis, treatment**
- the ups and downs of multiple sclerosis therapy (Hohlfeld and Wiendl) 2001;49:283 (Editorial)
- Muscular dystrophy**
- distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype (Illa et al) 2001;49:130
- gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations (Wagner et al) 2001;49:706
- when running a stop sign may be a good thing (Karpati) 2001;49:693 (Editorial)
- Mutations**
- abnormal desmin protein in myofibrillar myopathies caused by desmin gene mutations (Li and Dalakas) 2001;49:532
- adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening (Bezman et al) 2001;49:512
- clinical and pathological features of a parkinsonian syndrome in a family with an ALA53Thr gamma-stnuclein mutation (Spira et al) 2001;49:313
- compound heterozygous D90A and D96N SOD1 mutations in a recessive amyotrophic lateral sclerosis family (Hand et al) 2001;49:267
- distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype (Illa et al) 2001;49:130
- Down's syndrome fibroblasts anticipate the accumulation of specific ageing-related mtDNA mutations (Del Bo et al) 2001;137:138
- evidence for digenic inheritance in a family with both febrile convulsions and temporal lobe epilepsy implicating chromosomes 18qter and 1q25-231 (Baulac et al) 2001;49:786
- familial atypical progressive supranuclear palsy associated with homozygosity for the delN296 mutation in the tau gene (Pastor et al) 2001;49:263
- further evidence that neurofilament light chain gene mutations can cause Charcot-Marie-Tooth disease type 2E (De Jonghe et al) 2001;49:245
- gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations (Wagner et al) 2001;49:706
- germline mutations in the *CCM1* gene, encoding Krit1, cause cerebral cavernous malformations (Lucas et al) 2001;49:529
- inherited myoclonus-dystonia syndrome: narrowing the 7q21-q31 locus in German families (Asmus et al) 2001;49:121
- mutations in the complex I *NDUFS2* gene of patients with cardiomyopathy and encephalomyopathy (Loeffen et al) 2001;49:195
- novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy (Grabowski et al) 2001;49:697
- novel mtDNA mutation in the ND5 subunit of complex I in two MELAS patients (Corona et al) 2001;49:106
- a novel TRK A (*NTRK1*) mutation associated with hereditary sensory and autonomic neuropathy type V (Houlden et al) 2001;49:521
- positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the *Parkin* gene (Hilker et al) 2001;49:367
- SCA12 is a rare locus for autosomal dominant cerebellar ataxia: a study of an Indian family (Fujigasaki et al) 2001;49:117
- subclinical cerebellar impairment in the common types of migraine: a three-dimensional analysis of reaching movements (Sándor et al) 2001;49:668
- SURF1 gene mutation presenting as isolated leukodystrophy (Rahman et al) 2001;49:805
- when running a stop sign may be a good thing (Karpati) 2001;49:693 (Editorial)
- Myoclonus**
- lack of activation of human secondary somatosensory cortex in Unverricht-Lundborg type of progressive myoclonus epilepsy (Forss et al) 2001;49:90
- Myoclonus-dystonia syndrome**
- inherited myoclonus-dystonia syndrome: narrowing the 7q21-q31 locus in German families (Asmus et al) 2001;49:121
- Myopathy**
- abnormal desmin protein in myofibrillar myopathies caused by desmin gene mutations (Li and Dalakas) 2001;49:532
- antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia (Lodi et al) 2001;49:590

distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype (Illa et al) 2001;49:130

exercise intolerance in mitochondrial myopathy is not related to lactic acidosis (Vissing et al) 2001;49:672

incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA abnormalities (Darin et al) 2001;49:377

late-onset mitochondrial DNA depletion: DNA copy number, multiple deletions, and compensation (Barthélémy et al) 2001;49:607

mutations in the complex I *NDUFS2* gene of patients with cardiomyopathy and encephalomyopathy (Loeffen et al) 2001;49:195

a novel autosomal dominant distal myopathy with early respiratory failure: clinico-pathologic characteristics and exclusion of linkage to candidate genetic loci (Chinnery et al) 2001;49:443

sequence-selective DNA binding drugs mithramycin A and chromomycin A<sub>3</sub> are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons (Chatterjee et al) 2001;49:345

### **Narcolepsy**

hypocretin deficiency in familial symptomatic narcolepsy (Melberg et al) 2001;49:136 (Letter)

### **NBQX**

subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease (Blandini et al) 2001;49:525

### **Neuroimaging**

absence of *N*-acetylaspartate in the human brain: impact on neurospectroscopy? (Martin et al) 2001;49:518

*N*-acetyl aspartate-a neuronal marker? (Barker) 2001;49:423 (Editorial)

effects of seasons on magnetic resonance imaging-measured disease activity in patients with multiple sclerosis (Rovaris et al) 2001;49:415 (Letter)

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on MRI-measured disease activity and burden in patients with relapsing multiple sclerosis (Comi et al) 2001;49:290

irreversible brain creatine deficiency with elevated serum and urine creatine: a creatine transporter defect? (Cecil et al) 2001;49:401

a longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions (Bitsch et al) 2001;49:793

perfusion magnetic resonance abnormalities in patients with sickle cell disease (Kirkham et al) 2001;49:477

postnatal maturation of human GABA<sub>A</sub> receptors measured with positron emission tomography (Chugani et al) 2001;49:618

right lateralized motor cortex activation during volitional blinking (Eimeren et al) 2001;49:813

stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia (Schellinger et al) 2001;49:460

texture analysis of morphological processing of magnetic resonance imaging assist detection of focal cortical dysplasia in extra-temporal partial epilepsy (Bernasconi et al) 2001;49:770

tracking post-stroke recovery with magnetoencephalography (Rossini) 2001;49:136 (Letter)

tracking post-stroke recovery with magnetoencephalography (Rossini) 2001;49:136 (Letter)

### **Neurological disorders**

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

presence of *Chlamydia pneumoniae* DNA in the cerebral spinal fluid is a common phenomenon in a variety of neurological diseases and not restricted to multiple sclerosis (Gieffers et al) 2001;49:585

### **Neurons**

loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment (Kordower et al) 2001;49:202

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

selective alterations in glutamate and GABA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers (White et al) 2001;49:67

sequence-selective DNA binding drugs mithramycin A and chromomycin A<sub>3</sub> are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons (Chatterjee et al) 2001;49:345

superoxide stress identifies neurons at risk in a model of ataxia-telangiectasia (Quick and Dugan) 2001;49:627

### **Neuropeptides**

neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation (Nelson et al) 2001;49:597

### **Neurotrophins**

neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation (Nelson et al) 2001;49:597

### **Nicotinamide**

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

### **Nipah virus**

treatment of acute Nipah encephalitis with ribavirin (Chong et al) 2001;49:810

### **Nitric oxide**

electrically active axons degenerate when exposed to nitric oxide (Smith et al) 2001;49:740

### **Nociception**

is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? (Ebersberger et al) 2001;49:7

### **Nutritional supplements**

antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia (Lodi et al) 2001;49:590

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

### **Ocular oscillations**

ocular oscillations induced by shifts of the direction and depth of visual fixation (Bhidayasiri et al) 2001;49:24

### **Oligodendroglia**

platelet-derived growth factor-(alpha symbol) receptor-positive oligodendroglia are frequent in multiple sclerosis lesions (Maeda et al) 2001;49:776

## **Oxidative stress**

- role of mitochondrial dysfunction and dopamine-dependent oxidative stress in amphetamine-induced toxicity (Lotharius and O'Malley) 2001;49:79
- sequence-selective DNA binding drugs mithramycin A and chromomycin A<sub>3</sub> are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons (Chatterjee et al) 2001;49:345
- superoxide stress identifies neurons at risk in a model of ataxia-telangiectasia (Quick and Dugan) 2001;49:627

## **Pain**

- (alpha symbol)-adrenergic supersensitivity of the sudomotor nerve in complex regional pain syndrome (Ch?mali et al) 2001;49:453
- mechanisms and predictors of chronic facial pain in lateral medullary infarction (Fitzek et al) 2001;49:493
- a novel TRK A (*NTRK1*) mutation associated with hereditary sensory and autonomic neuropathy type V (Houlden et al) 2001;49:521

## **Paralysis**

- sexual arousal and orgasm in women: effects of spinal cord injury (Spiski et al) 2001;49:35

## **Paraneoplastic antibodies**

- anti-Yo antibodies and cerebellar degeneration in a man with adenocarcinoma of the esophagus (Sutton et al) 2001;49:253
- CRMP-5 neuronal autoantibody: marker for lung cancer and thymoma-related autoimmunity (Yu et al) 2001;49:146
- paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy (Antoine et al) 2001;49:214
- yet another paraneoplastic antibody (Posner and Dalmau) 2001;49:141 (Editorial)

## **Paraparesis, spastic**

- variable phenotype of Alzheimer's disease with spastic paraparesis (Smith et al) 2001;49:276 (Letter)

## **Parkinson's disease, clinicopathology**

- clinical and pathological features of a parkinsonian syndrome in a family with an A53T  $\gamma$ -synuclein mutation (Spira et al) 2001;49:313
- familial amyotrophic lateral sclerosis and parkinsonism-dementia complex of the Kii Peninsula of Japan: clinical and neuropathological study and tau analysis (Kuzuhara et al) 2001;49:501

## **Parkinson's disease, genetics**

- no evidence of association between a dopamine transporter gene polymorphism (1215A/G) and Parkinson's disease (Kimura et al) 2001;49:276 (Letter)
- Parkinson's disease is not associated with the combined  $\alpha$ -synuclein/apolipoprotein E susceptibility genotype (Khan et al) 2001;49:665
- positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the *Parkin* gene (Hilker et al) 2001;49:367

## **Parkinson's disease, pathology**

- abnormal activity in the globus pallidus in off-period dystonia (Hashimoto et al) 2001;49:242
- biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover (Fuente-Fernández et al) 2001;49:298

- subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease (Blandini et al) 2001;49:525

## **Parkinson's disease, treatment**

- deep brain stimulation for Parkinson's disease (Delong and Wichmann) 2001;49:142 (Editorial)
- functional correlates of pallidal stimulation for Parkinson's disease (Fukuda et al) 2001;49:155
- the neurochemistry of therapeutics: levodopa pharmacodynamics in Parkinson's disease (Frey) 2001;49:285 (Editorial)
- subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease (Blandini et al) 2001;49:525

## **Peripheral neuropathy**

- paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy (Antoine et al) 2001;49:214

## **Peroxisome proliferator-activated receptors**

- role for peroxisome proliferator-activated receptor- $\gamma$  in Alzheimer's disease (Heneka et al) 2001;49:276 (Letter)

## **Pick disease**

- focal dementia syndromes: in search of the gold standard (Petersen) 2001;49:421 (Editorial)

## **Placebos**

- placebos on trial (Moreno) 2001;49:558 (Editorial)

## **Platelet-derived growth factor-(alpha symbol) receptor**

- platelet-derived growth factor-(alpha symbol) receptor-positive oligodendroglia are frequent in multiple sclerosis lesions (Maeda et al) 2001;49:776

## **Positron emission tomography**

- postnatal maturation of human GABA<sub>A</sub> receptors measured with positron emission tomography (Chugani et al) 2001;49:618
- right lateralized motor cortex activation during volitional blinking (Eimeren et al) 2001;49:813

## **Progressive multifocal leukoencephalopathy**

- cellular and humoral immune response in progressive multifocal leukoencephalopathy (Weber et al) 2001;49:636

## **Progressive supranuclear palsy**

- familial atypical progressive supranuclear palsy associated with homozygosity for the delN296 mutation in the tau gene (Pastor et al) 2001;49:263

## **Propofol**

- propofol in subanesthetic doses terminates status epilepticus in a rodent model (Holtkamp et al) 2001;49:260

## **Reactive oxygen species**

- superoxide stress identifies neurons at risk in a model of ataxia-telangiectasia (Quick and Dugan) 2001;49:627

## **Receptors, adenosine**

- adenosine A<sub>2A</sub> receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage (Mayne et al) 2001;49:727

## **Receptors, GABA<sub>A</sub>**

- postnatal maturation of human GABA<sub>A</sub> receptors measured with positron emission tomography (Chugani et al) 2001;49:618

## **Receptors, peroxisome proliferator-activated**

- role for peroxisome proliferator-activated receptor- $\gamma$  in Alzheimer's disease (Heneka et al) 2001;49:276 (Letter)

- Receptors, platelet-derived growth factor-(alpha symbol)**  
platelet-derived growth factor- $\alpha$  receptor-positive oligodendroglia are frequent in multiple sclerosis lesions (Maeda et al) 2001;49:776
- Restless legs syndrome**  
intermediate CAG repeat lengths (53,54) for MJD/SCA3 are associated with an abnormal phenotype (Alfen et al) 2001;49:797
- Retinitis**  
HSV-induced retinitis following herpes simplex encephalitis: indications for brain-to-eye transmission of HSV-1 (Maertzdorf et al) 2001;49:104
- Ribavirin**  
treatment of acute Nipah encephalitis with ribavirin (Chong et al) 2001;49:810
- Riboflavin**  
potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561
- Riluzole**  
effects of riluzole on cortical excitability in patients with amyotrophic lateral sclerosis (Stefan et al) 2001;49:536
- RNA, messenger**  
intron 7 retention and exon 9 skipping EAAT2 mRNA variants are not associated with amyotrophic lateral sclerosis (Flowers et al) 2001;49:643  
selective alterations in glutamate and GABA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers (White et al) 2001;49:67
- Seizures; see also Epilepsy**  
evidence for digenic inheritance in a family with both febrile convulsions and temporal lobe epilepsy implicating chromosomes 18qter and 1q25-q31 (Baulac et al) 2001;49:786  
focal cooling rapidly terminates experimental neocortical seizures (Yang & Rothman) 2001;49:721  
how does ACTH work against infantile spasms? Bedside to bench (Snead) 2001;49:288 (Editorial)  
how long do new-onset seizures in children last? (Shinnar et al) 2001;49:659  
propofol in subanesthetic doses terminates status epilepticus in a rodent model (Holtkamp et al) 2001;49:260
- Sensory neuropathy**  
a novel TRK A (*NTRK1*) mutation associated with hereditary sensory and autonomic neuropathy type V (Houlden et al) 2001;49:521
- Sexual function**  
sexual arousal and orgasm in women: effects of spinal cord injury (Spiski et al) 2001;49:35
- Sickle cell disease**  
improved cerebrovascular patency following therapy in patients with sickle cell disease: initial results in 4 patients who received HLA-identical hematopoietic stem cell allografts (Steen et al) 2001;49:222  
perfusion magnetic resonance abnormalities in patients with sickle cell disease (Kirkham et al) 2001;49:477
- Somatosensory cortex**  
lack of activation of human secondary somatosensory cortex in Unverricht-Lundborg type of progressive myoclonus epilepsy (Forss et al) 2001;49:90
- Spasticity**  
variable phenotype of Alzheimer's disease with spastic paraparesis (Smith et al) 2001;49:125
- Spinal cord injury**  
sexual arousal and orgasm in women: effects of spinal cord injury (Spiski et al) 2001;49:35
- Spinocerebellar ataxia**  
intermediate CAG repeat lengths (53,54) for MJD/SCA3 are associated with an abnormal phenotype (Alfen et al) 2001;49:797
- Statins**  
plasma levels of amyloid  $\beta$  proteins did not differ between subjects taking statins and those not taking statins (Tokuda et al) 2001;49:546 (Letter)
- Status epilepticus**  
propofol in subanesthetic doses terminates status epilepticus in a rodent model (Holtkamp et al) 2001;49:260
- Stem cell graft**  
improved cerebrovascular patency following therapy in patients with sickle cell disease: initial results in 4 patients who received HLA-identical hematopoietic stem cell allografts (Steen et al) 2001;49:222
- Stroke**  
tracking post-stroke recovery with magnetoencephalography (Rossini) 2001;49:136 (Letter)
- Substantia nigra**  
subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease (Blandini et al) 2001;49:525
- Sudomotor nerve**  
 $\alpha$ -adrenergic supersensitivity of the sudomotor nerve in complex regional pain syndrome (Chémali et al) 2001;49:453
- Superoxide stress**  
superoxide stress identifies neurons at risk in a model of ataxia-telangiectasia (Quick and Dugan) 2001;49:627
- $\alpha$ -Synuclein**  
Parkinson's disease is not associated with the combined  $\alpha$ -synuclein/apolipoprotein E susceptibility genotype (Khan et al) 2001;49:665
- Tat protein**  
HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors (Johnston et al) 2001;49:230
- Tau protein**  
the case of the missing tau, or, why didn't the mRNA bark? (Bird and Schellenberg) 2001;49:144 (Editorial)  
familial amyotrophic lateral sclerosis and parkinsonism-dementia complex of the Kii Peninsula of Japan: clinical and neuropathological study and tau analysis (Kuzuhara et al) 2001;49:501  
familial atypical progressive supranuclear palsy associated with homozygosity for the delN296 mutation in the tau gene (Pastor et al) 2001;49:263  
honorable compromise regarding amyloid in Alzheimer's disease (Terry) 2001;49:684 (Letter)  
the hound that did not bark in the night (Schaumburg) 2001;49:817 (Letter)  
loss of brain tau defines novel sporadic and familial tauopathies with frontotemporal dementia (Zhukareva et al) 2001;49:165  
a novel autosomal dominant distal myopathy with early respiratory failure: clinico-pathologic characteristics and exclusion of linkage to candidate genetic loci (Chinnery et al) 2001;49:443  
tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231 (Hampel et al) 2001;49:545 (Letter)



## **T cells**

are transfectant cells essential for measuring cytotoxic T cells in paraneoplastic cerebellar degeneration? (Tanaka and Tanaka) 2001;49:686 (Letter)

## **Temporal lobe**

patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease (Chan et al) 2001;49:433

## **Thymoma**

CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity (Yu et al) 2001;49:146

## **Tic disorder**

children with comorbid attention-deficit-hyperactivity disorder and tic disorder: evidence for additive inhibitory deficits within the motor system (Moll et al) 2001;49:393

## **Tissue plasminogen activator**

apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke (Broderick et al) 2001;49:736

## **Tomography, emission computed**

positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the *Parkin* gene (Hilker et al) 2001;49:367

## **Tremor**

risk of tremor and impairment from tremor in relatives of patients with essential tremor: a community-based family study (Louis et al) 2001;49:761

## **Tuberous sclerosis**

selective alterations in glutamate and GABA receptor subunit mRNA expression in dysplastic neurons and giant cells of cortical tubers (White et al) 2001;49:67

## **Tumor markers**

CRMP-5 neuronal autoantibody: marker for lung cancer and thymoma-related autoimmunity (Yu et al) 2001;49:146

## **Twins**

causes of epilepsies: insights from discordant monozygotic twins (Briellmann et al) 2001;49:45

## **Tyrosine phosphate**

laforin is a cell membrane and endoplasmic reticulum-associated protein tyrosine phosphatase (Minassian et al) 2001;49:271

## **Ullrich's disease**

collagen VI deficiency in Ullrich's disease (Higuchi et al) 2001;49:544 (Letter)

## **Unverricht-Lundborg disease**

lack of activation of human secondary somatosensory cortex in Unverricht-Lundborg type of progressive myoclonus epilepsy (Forss et al) 2001;49:90

## **Visual fields**

care should be taken in interpretation of visual field tests in children (Vanhatalo) 2001;49:277 (Letter)

## **Vitamins, antioxidant**

antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia (Lodi et al) 2001;49:590

potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders (Tarnopolsky & Beal) 2001;49:561

## **X-linked adrenoleukodystrophy**

evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy (Van Geel et al) 2001;49:186



